876147-43-2

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Hydroxymethyl-azepane-1-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into complex drug molecules, potentially enhancing their efficacy and selectivity.
Used in Agrochemical Development:
In the agrochemical industry, 3-Hydroxymethyl-azepane-1-carboxylic acid tert-butyl ester is used as a precursor in the development of new pesticides and herbicides, leveraging its chemical properties to improve the performance of these products.
Used in Materials Science:
3-Hydroxymethyl-azepane-1-carboxylic acid tert-butyl ester is utilized as a component in the development of new materials, where its unique structure can contribute to the creation of advanced materials with specific properties for various applications.
Used in Drug Development:
Due to its potential biological activity, 3-Hydroxymethyl-azepane-1-carboxylic acid tert-butyl ester is used in the research and development of new drugs and therapies, where it may contribute to the discovery of novel medicinal compounds with improved pharmacological profiles.

Upstream product

• 33241-96-2 1-Benzyl-hexahydro-azepin-2-on 
• 105-60-2 caprolactam 
• 61472-23-9 hexahydroazepin-3-yl-methanol 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE

The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.